Resistance to aspirin in increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels

被引：73

作者：

Borna C. ^{[1
]}

Lazarowski E. ^{[2
]}

van Heusden C. ^{[2
]}

Öhlin H. ^{[1
]}

Erlinge D. ^{[1
]}

机构：

[1] Department of Cardiology, Heart and Lung Division, Lund University Hospital, Lund

[2] Department of Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC

来源：

Thrombosis Journal | / 3卷 / 1期

关键词：

Acute coronary syndromes; ADP; Aspirin; Platelets;

D O I：

10.1186/1477-9560-3-10

中图分类号：

学科分类号：

摘要：

Background: To be fully activated platelets are dependent on two positive feedback loops; the formation of thromboxane A2 by cyclooxygenase in the platelets and the release of ADP. We wanted to evaluate the effect of aspirin on platelet function in patients with acute coronary syndromes and we hypothesized that increased levels of ADP in patients with acute coronary syndromes could contribute to aspirin resistance. Methods: Platelet activity in 135 patients admitted for chest pain was assessed with PFA-100. An epinephrine-collagen cartridge (EPI-COLL) was used for the detection of aspirin resistance together with an ADP-collagen cartridge (ADP-COLL). ADP was measured with hplc from antecubital vein samples. Three subgroups were compared: chest pain with no sign of cardiac disease (NCD), NonST-elevation myocardial infarction (NSTEMI) and STEMI. Results: Platelet activation was increased for the STEMI group compared NCD. Aspirin resistance defined as < 193 sec in EPI-COLL was 9.7 % in NCD, and increased to 26.0 % (n.s.) in NSTEMI and 83.3 % (p < 0.001) in STEMI. Chronic aspirin treatment significantly reduced platelet aggregation in NCD and NSTEMI, but it had no effect in STEMI. Plasma levels of ADP were markedly increased in STEMI (905 ± 721 nmol/1, p < 0.01), but not in NSTEMI (317 ± 245), compared to NCD (334 ± 271, mean ± SD). ADP levels correlated with increased platelet activity measured with ADP-COLL (r = -0.30, p < 0.05). Aspirin resistant patients (EPI-COLL < 193 sec) had higher ADP levels compared to aspirin responders (734 ± 807 vs. 282 ± 187 nmol/l, mean ± SD, p < 0.05). Conclusion: Platelets are activated and aspirin resistance is more frequent in STEMI, probably due to a general activation of platelets. ADP levels are increased in STEMI and correlates with platelet activation. Increased levels of ADP could be one reason for increased platelet activity and aspirin resistance. © 2005 Borna et al; licensee BioMed Central Ltd.

引用

页数：9

共 28 条

[1] Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, pp. 71-86, (2002)
[2] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, 348, pp. 1329-1339, (1996)
[3] Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, New Engl. J. Med., 345, pp. 494-502, (2001)
[4] Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., Topol E.J., Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial, Jama, 288, pp. 2411-2420, (2002)
[5] Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., Brizard A., Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate, Thromb. Res., 107, pp. 45-49, (2002)
[6] Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., Topol E.J., Profile and prevalence of aspirin resistance in patients with cardiovascular disease, Am. J. Cordiol., 88, pp. 230-235, (2001)
[7] Grotemeyer K.H., Scharafinski H.W., Husstedt I.W., Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients, Thromb. Res., 71, pp. 397-403, (1993)
[8] Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E., A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease, J. Am. Coll. Cordial., 41, pp. 961-965, (2003)
[9] Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., Yusuf S., Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events, Circulation, 105, pp. 1650-1655, (2002)
[10] Kundu S.K., Heilmann E.J., Sio R., Garcia C., Davidson R.M., Ostgaard R.A., Description of an in vitro platelet function analyzer-PFA-100, Semin. Thromb. Hemost., 21, SUPPL. 2, pp. 106-112, (1995)

← 1 2 3 →